

Product datasheet for TL302936V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

NMNAT3 Human shRNA Lentiviral Particle (Locus ID 349565)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: NMNAT3 Human shRNA Lentiviral Particle (Locus ID 349565)

Locus ID: 349565

Synonyms: FKSG76; PNAT-3; PNAT3

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: NMNAT3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001200047, NM 001320510, NM 001320511, NM 001320512, NM 001320513,

NM 178177, NM 178177.1, NM 178177.2, NM 178177.3, NM 178177.4, NM 001200047.1,

NM 001200047.2, BC034374, BC034374.1, BC036218, NM 001363968

UniProt ID: Q96T66

Summary: This gene encodes a member of the nicotinamide/nicotinic acid mononucleotide

adenylyltransferase family. These enzymes use ATP to catalyze the synthesis of nicotinamide

adenine dinucleotide or nicotinic acid adenine dinucleotide from nicotinamide

mononucleotide or nicotinic acid mononucleotide, respectively. The encoded protein is localized to mitochondria and may also play a neuroprotective role as a molecular

chaperone. Alternatively spliced transcript variants encoding multiple isoforms have been

observed for this gene. [provided by RefSeq, Jan 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).